Horizons in world cardiovascular research. Volume 2 /
| Други автори: | Bennington, Eleanor H. |
|---|---|
| Формат: | Електронна книга |
| Език: | English |
| Публикувано: |
New York :
Nova Biomedical Books,
℗♭2010.
|
| Серия: |
Horizons in world cardiovascular research series.
|
| Предмети: | |
| Онлайн достъп: |
http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=383220 |
| Подобни документи: |
Print version::
Horizons in World Cardiovascular Research. |
Съдържание:
- ""HORIZONS IN WORLDCARDIOVASCULAR RESEARCH. VOLUME 2""; ""HORIZONS IN CARDIOVASCULAR RESEARCH""; ""CONTENTS""; ""PREFACE""; ""BENEFICIAL CLINICAL EFFECTS OF PERHEXILINEIN CARDIAC PATIENTS: MULTIPLE BIOCHEMICALMECHANISMS""; ""ABSTRACT""; ""CLINICAL APPLICATIONS OF PERHEXILINE""; ""Stable and Unstable Angina Pectoris""; ""Aortic Stenosis""; ""Heart Failure""; ""PHARMACOKINETICS AND TOXICITY OF PERHEXILINE""; ""PHARMACOLOGY OF PERHEXILINE""; ""Hemodynamics""; ""Ion Channels""; ""Metabolic Shift""; ""Interactions with NO Signaling Pathway""; ""NO resistance in cardiovascular disease states""
- ""Mechanisms of NO resistance""""Amelioration of platelet NO resistance by perhexiline""; ""Oxidative Stress and Inflammation""; ""CONCLUSION AND FUTURE PERSPECTIVES""; ""REFERENCES""; ""DRUG-INDUCED VALVULAR HEART DISEASE""; ""ABSTRACT""; ""1. INTRODUCTION""; ""2. PATHOPHYSIOLOGY OF DRUG-INDUCED VALVULAR HEARTDISEASE""; ""2.1. Serotonin Metabolism""; ""2.2. The Serotonin Transporter (SERT)""; ""2.3. Role of the 5-HT2B Receptor in Drug-Induced Valvular Heart Disease""; ""3. MORPHOLOGICAL AND ECHOCARDIOGRAPHIC CHARACTERISTICS""; ""3.1. Histopathological Features""
- ""3.2. Echocardiographical Characteristics""""4. DRUGS ASSOCIATED WITH VALVULAR HEART DISEASE""; ""4.1. Ergotamine and Methysergide""; ""4.2. Fenfluramine/Phentermine and Dexfenfluramine""; ""4.3. Pergolide and Cabergoline""; ""4.4. Bromocriptine""; ""4.5. 3,4-Methylenedioxymethamphetamine (MDMA, “Ecstasy�)""; ""4.6. Other Drugs""; ""5. INFLUENCE OF DRUG DOSE, TREATMENT DURATIONAND RISK FACTORS""; ""6. NATURAL COURSE OF TOXIC VALVULOPATHY""; ""7. SMALL ANIMAL MODELS OF DRUG-INDUCEDVALVULAR HEART DISEASE""; ""8. PRACTICAL RECOMMENDATIONS FOR THE USE OF POTENTIALVALVULOPATHIC DRUGS""
- ""ABBREVIATIONS""""REFERENCES""; ""SHARED SUSCEPTIBILITY GENES OF METABOLICSYNDROME AND CARDIOVASCULAR DISEASE""; ""ABSTRACT""; ""INTRODUCTION""; ""The Renin Angiotensin System""; ""Trigylecrid Metabolism Affecting Genetic Variants""; ""Genetic Factors in Glucose Homeostasis""; ""Mutations Involved in Inflammatory Pathways""; ""Other Contributing Genetic Factors""; ""CONCLUDING REMARKS""; ""REFERENCES""; ""CARDIAC PACING: A REVIEW CHAPTER""; ""ABSTRACT""; ""INTRODUCTION""; ""ELECTRICAL CONDUCTION""; ""Blood Pressure""; ""Cardiac Output""; ""Stroke Volume""
- ""CLINICAL CARDIAC PACING INDICATIONS""""Atrioventricular (AV) Block""; ""Sinus Node Abnormalities""; ""INTRAVENTRICULAR CONDUCTION""; ""Cardiac Pacing Therapies""; ""Transcutaneous Pacing""; ""Temporary Transvenous Pacing""; ""Permanent Transvenous Pacing""; ""OVERVIEW OF PACEMAKERS""; ""Single Chamber Pacing Operation""; ""TRANSESOPHAGEAL PACING AND MECHANICAL CARDIAC PACING""; ""Transesophageal Pacing""; ""Mechanical Cardiac Pacing""; ""Pharmacological Remedies""; ""FOLLOW-UP""; ""SUMMARY""; ""REFERENCES""